The Fly | MCRB

First FDA-Approved Oral Microbiome Therapeutic: VOWST (SER-109) is the first and only FDA-approved oral microbiome therapeutic, establishing Seres as a commercial-stage company with a validated product for recurrent C. difficile infection (CDI).

Pioneering Microbiome Development Platform: Seres has developed a leading, proprietary platform for identifying, designing, and manufacturing complex live bacterial therapeutics, leveraging deep scientific understanding of the human microbiome.

Proprietary Manufacturing Capabilities: The company possesses specialized and scalable cGMP manufacturing processes for its complex microbiome-based products, representing a unique capability and significant barrier to entry for competitors.

Clinical Development Failure Risk: Failure of future clinical trials for pipeline candidates could prevent new product approvals and revenue streams.

Commercialization & Market Adoption Risk: Despite VOWST's approval, its market adoption and ability to generate significant revenue, as well as the commercial success of future products, are uncertain.

Regulatory Pathway Uncertainty Risk: Obtaining regulatory approval for pipeline candidates, especially with novel microbiome approaches, remains uncertain and could face delays or rejections.

Clinical Development Failure Risk: Failure of future clinical trials for pipeline candidates could prevent new product approvals and revenue streams.

Regulatory Pathway Uncertainty Risk: Obtaining regulatory approval for pipeline candidates, especially with novel microbiome approaches, remains uncertain and could face delays or rejections.

Today

Morning Movers: Beazer jumps after revised Dream Finders acquisition proposal

9:05 AM

Seres Therapeutics announces top-line results from SER-155 trial